AOZORA (jRCT1080224629, https://jrct.niph.go.jp) is a postmarketing clinical study designed to evaluate the long-term safety and joint-health effects of emicizumab in people with severe hemophilia A (PwSHA) aged <12 years, without FVIII inhibitors [26]. This evidence concerns the gene F8 and hemophilia A.